How beta blocker medicines might protect bone after menopause
Molecular and cellular mechanisms of prevention of bone loss by beta blockers
This research looks at whether certain beta blocker medicines can help protect bone density in women after menopause.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mainehealth NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11189800 on NIH RePORTER |
What this research studies
Researchers will study why beta blockers appear to help prevent postmenopausal bone loss by combining human genetic and molecular data with lab experiments. They will examine gene differences (like ADRB1) and small RNA molecules (such as miR-19a-3p) that may change how people respond to beta blockers. In the lab they will use mouse and cell studies to see how these drugs affect bone cells called osteoclasts and osteoblasts. The goal is to link lab findings to human data so doctors can better choose which beta blocker and which patients might benefit most.
Who could benefit from this research
Good fit: Ideal candidates are postmenopausal women at risk for osteoporosis or early bone loss who might be eligible for beta blocker treatment or sample donation for genetic/molecular studies.
Not a fit: People with bone loss from causes unrelated to menopause, those with contraindications to beta blockers, or men are less likely to benefit from this research.
Why it matters
Potential benefit: If successful, this work could guide safer, more personalized use of beta blockers to help prevent bone loss after menopause.
How similar studies have performed: Human observational studies have linked B1-selective beta blockers with better bone outcomes while prior mouse work pointed to B2 receptors, so parts of this approach are supported but the exact mechanism and personalized links are still novel.
Where this research is happening
Portland, United States
- Mainehealth — Portland, United States (Active)
Researchers
- Principal investigator: Motyl, Katherine Jean — Mainehealth
- Study coordinator: Motyl, Katherine Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.